Dualitybio Inc.
Clinical trials sponsored by Dualitybio Inc., explained in plain language.
Upcoming readouts
Trials from this sponsor expected to report results within the next 12 months.
- New hope for advanced cancer: experimental drug DB-1419 enters human trials Results expected Feb 2027 (estimated)
- New lupus drug enters early human testing Results expected Jun 2027 (estimated)
- New hope for Hard-to-Treat HER2 cancers? early trial launches Results expected Aug 2027 (estimated)
- New hope for Hard-to-Treat cancers: DB-1305 enters human trials Results expected Aug 2027 (estimated)
-
New hope for hard-to-treat breast cancer: targeted drug takes on chemo in major trial
Disease control OngoingThis study tests a new drug, DB-1303, against standard chemotherapy in about 540 people with a specific type of advanced breast cancer (HER2-low, hormone receptor-positive) that has stopped responding to hormone therapy. The main goal is to see if DB-1303 can delay cancer growth …
Phase 3 • Sponsor: DualityBio Inc. • Aim: Disease control
Last updated Jun 27, 2026 13:00 UTC
-
New hope for Hard-to-Treat cancers: DB-1305 enters human trials
Disease control OngoingThis study tests a new drug called DB-1305/BNT325 in adults with advanced solid tumors that have not responded to standard treatments. The goal is to find a safe dose and see if it can shrink tumors. About 1,100 participants will take part in this early-phase trial.
Phase 1/2 • Sponsor: DualityBio Inc. • Aim: Disease control
Last updated Jun 27, 2026 12:31 UTC
-
New hope for advanced breast cancer: DB-1303 takes on T-DM1 in major trial
Disease control OngoingThis Phase 3 trial compares a new drug called DB-1303 (also known as BNT323) to the current standard treatment T-DM1 in 228 people with HER2-positive breast cancer that cannot be removed by surgery or has spread to other parts of the body. All participants have already been treat…
Phase 3 • Sponsor: DualityBio Inc. • Aim: Disease control
Last updated Jun 27, 2026 07:55 UTC